389 completed, 101 terminated, 73 unknown, 50 recruiting. 677 Phase 3, 104 Phase 2.
Follow Gastroenteritis: new trials by email Literature Review of Gastroenteritis trials Research Report on Gastroenteritis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Methadone as an Alternative Treatment for Children Underdoing HSCT PCA plus methadone (Experimental), PCA Alone (SOC) - Leukemia, Aplastic Anemia | Phase 3 | Suspended | University of Texas Southwestern Medical Center | 60 | 2028-01-01 | 2025-10-23 |
| Piperacillin/Tazobactam Versus Ceftriaxone and Metronidazole for Children With Perforated Appendicitis Piperacillin/Tazobactam, Ceftriaxone + Metronidazole - Appendicitis Perforated, Appendectomy, Laparoscopic | Phase 3 | Not yet recruiting | McMaster Children's Hospital | 180 | 2027-04-01 | 2026-10-09 |
| Nitazoxanide as Adjunct Therapy in Mild-to-Moderate Ulcerative Colitis Nitazoxanide (NTZ) - Ulcerative Colitis (UC) | Phase 2 / Phase 3 | Not yet recruiting | Tanta University | 44 | 2027-01-01 | 2026-09-15 |
| Study to Evaluate the Efficacy and Safety of Ponesimod (VSP-128) in Patients With Moderately to Severely Active Ulcerative Colitis Ponesimod, Placebo - Ulcerative Colitis (UC) | Phase 3 | Recruiting | Vanda Pharmaceuticals | 150 | 2026-09-01 | 2026-08-18 |
| Vedolizumab for the Prevention of ICI Related Diarrhea or Colitis in Patients With Cancer Vedolizumab, Placebo - IrAE, Immune-related Adverse Event | Phase 2 / Phase 3 | Recruiting | AHS Cancer Control Alberta | 36 | 2026-08-13 | 2026-08-27 |
| Modafinil for Debilitating Fatigue in Quiescent Inflammatory Bowel Disease MODIFI-IBD Trial) Modafinil, Placebo - Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis), Chronic Fatigue | Phase 2 / Phase 3 | Recruiting | Radboud University Medical Center | 60 | 2026-08-03 | 2026-09-14 |
| Use of Dexmedetomidine to Improve Pain Control and Recovery After Laparocopic-Assisted Bowel Surgery in Adults Dexmedetomidine infusion, Postoperative matched placebo of 0.9% saline infusion - Bowel Diseases, Inflammatory, Bowel Surgery | Phase 3 | Not yet recruiting | Dr. Naveed Siddiqui | 70 | 2026-07-01 | 2026-06-24 |
| Hemay005 for the Treatment of Chinese Moderately to Severely Active Ulcerative Colitis Hemay005 tablet, Placebo - Ulcerative Colitis (UC) | Phase 3 | Not yet recruiting | Ganzhou Hemay Pharmaceutical Co., Ltd | 360 | 2026-06-01 | 2026-06-16 |
| A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis JNJ-78934804, Guselkumab - Colitis, Ulcerative | Phase 3 | Recruiting | Janssen Research & Development, LLC | 644 | 2026-05-23 | 2026-11-03 |
| A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease JNJ-78934804, Guselkumab - Crohn Disease | Phase 3 | Recruiting | Janssen Research & Development, LLC | 460 | 2026-05-22 | 2026-11-03 |
| Vancomycin Taper to Prevent Recurrent Clostridioides Difficile Fidaxomicin, Vancomycin capsule - Clostridia Difficile Colitis | Phase 3 | Recruiting | McGill University Health Centre/Research Institute of the McGill University Health Centre | 500 | 2026-04-24 | 2026-09-23 |
| A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease Guselkumab, Risankizumab - Crohn Disease | Phase 3 | Recruiting | Janssen Research & Development, LLC | 530 | 2026-04-21 | 2026-11-03 |
| Holy Basil in The Treatment of Dyspepsia Holy basil extract - Dyspepsia and Other Specified Disorders of Function of Stomach | Phase 2 / Phase 3 | Recruiting | Mahidol University | 27 | 2026-02-13 | 2026-03-24 |
| A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease Duvakitug, Placebo - Crohn's Disease | Phase 3 | Recruiting | Sanofi | 751 | 2026-01-22 | 2026-10-21 |
| A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis Duvakitug, Placebo - Ulcerative Colitis | Phase 3 | Recruiting | Sanofi | 751 | 2026-01-16 | 2026-10-16 |
| A Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food Pipe): Eosinophilic Esophagitis dupilumab - Eosinophilic Esophagitis (EoE) | Phase 3 | Recruiting | Regeneron Pharmaceuticals | 20 | 2025-11-10 | 2026-09-29 |
| A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD) Vedolizumab SC, No Intervention - Ulcerative Colitis, Crohn's Disease | Phase 3 | Recruiting | Takeda | 70 | 2025-10-27 | 2026-10-09 |
| Risankizumab for Fibrostenotic Crohn's Disease Treatment Ustekinumab, Risankizumab - Crohn Disease, Crohn Disease and Ulcerative Colitis | Phase 3 | Not yet recruiting | First Affiliated Hospital of Wenzhou Medical University | 260 | 2025-10-20 | 2025-09-16 |
| An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis Duvakitug, Placebo - Ulcerative Colitis | Phase 3 | Recruiting | Sanofi | 980 | 2025-10-08 | 2026-10-23 |
| A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease Icotrokinra, Placebo - Crohn Disease | Phase 2 / Phase 3 | Recruiting | Janssen Research & Development, LLC | 1092 | 2025-10-03 | 2026-11-03 |
Showing 20 of 677. Sign in to see all of them.
Crohn Disease (238) · Colitis, Ulcerative (223) · Inflammatory Bowel Diseases (97) · Mucositis (33) · Eosinophilic Esophagitis (28) · Diarrhea (24) · Colitis (20) · Esophagitis, Peptic (19) · Gastrointestinal Diseases (18) · Appendicitis (17) · Enterocolitis, Necrotizing (17) · Esophagitis (13) · Diverticulitis (12) · Gastritis (12)
Digestive System Diseases (666) · Gastrointestinal Diseases (659) · Intestinal Diseases (551) · Inflammatory Bowel Diseases (363) · Colonic Diseases (242) · Colitis (220) · Pathological Conditions, Signs and Symptoms (98) · Infections (56) · Signs and Symptoms (49) · Esophageal Diseases (47) · Hemic and Lymphatic Diseases (46) · Pathologic Processes (44) · Esophagitis (41) · Hematologic Diseases (40)
Mesalamine (57) · Adalimumab (43) · Infliximab (29) · vedolizumab (24) · Budesonide (23) · Certolizumab Pegol (16) · Azathioprine (15) · Ustekinumab (15) · risankizumab (13) · guselkumab (12) · mirikizumab (12) · ozanimod (10) · Fecal Microbiota Transplantation (9) · upadacitinib (9) · etrolizumab (8)
AbbVie (26) · Takeda (26) · Janssen Research & Development, LLC (25) · Bausch Health Americas, Inc. (17) · Shire (17) · Dr. Falk Pharma GmbH (16) · Abbott (14) · Celgene (13) · Eli Lilly and Company (12) · AstraZeneca (11) · UCB Pharma (11) · Ferring Pharmaceuticals (10) · Merck Sharp & Dohme LLC (10) · GlaxoSmithKline (9) · Pfizer (9)
United States (320) · Canada (212) · Germany (186) · Poland (180) · Belgium (173) · France (169) · Italy (160) · Israel (152) · United Kingdom (150) · Spain (149) · Czechia (138) · Australia (136) · Hungary (134) · Netherlands (134) · Japan (123)
PMID 29380251, PMID 32445184, PMID 37368103, PMID 40357993, PMID 19735233, PMID 20195905, PMID 26893500, PMID 29850873, PMID 30476584, PMID 31077827, PMID 31599001, PMID 32635680, PMID 32766762, PMID 32816215, PMID 32870265, PMID 32964215, PMID 33324993, PMID 33684552, PMID 34614208, PMID 35648151, PMID 35792493, PMID 36124702, PMID 36208720, PMID 36336750, PMID 36342120, PMID 36526796, PMID 36931693, PMID 37402275, PMID 37560161, PMID 38096402, PMID 38310565, PMID 38425446, PMID 40013523, PMID 41264726, PMID 41763462, PMID 21129076, PMID 25996351, PMID 26563167, PMID 27959607, PMID 28467869, PMID 29028981, PMID 29142515, PMID 29409871, PMID 29743836, PMID 29857145, PMID 29909019, PMID 30203005, PMID 30739254, PMID 31279870, PMID 31982148
2023 (30), 2017 (20), 2016 (12), 2019 (12), 2015 (11), 2018 (11), 2014 (9), 2004 (6), 2008 (6), 2025 (6), 2009 (5), 2005 (3), K01DK075478 (1), K08HD052885 (1), M01RR000070 (1)